URINARY TRACT INFECTIONS CAUSED BY EXTENDED-SPECTRUM BETA-LACTAMASE-PRODUCING ENTEROBACTERIACEAE IN PATIENTS TREATED AT ABASS NDAO HOSPITAL CENTER FROM APRIL 2020 TO DECEMBER 2024

The aim of this study was to evaluate the prevalence of extended-spectrum B-lactamase (ESBL)-producing Enterobacteriaceae causing urinary tract infections (UTIs), as well as their antibiotic resistance profiles. This retrospective study was conducted at the bacteriology laboratory of Abass Ndao Hospital between April 2020 and December 2024. Out of 5,277 urine samples, 779 met the criteria for Enterobacteriaceae-associated UTI (15%), with 260 strains identified as ESBL producers (33%). The majority of cases involved hospitalized patients (78%) compared to outpatients (22%), with a sex ratio of 1.76. The predominant species were Escherichia coli (65%) and Klebsiella pneumoniae (22%). The mean patient age was 57.4 years. ESBL-producing strains exhibited high resistance to amoxicillin, the amoxicillin-clavulanic acid combination, ticarcillin, and third-generation cephalosporins (100%). Conversely, good susceptibility was observed for imipenem (92.42%), amikacin (89.16%), colistin (94.85%), and fosfomycin (72.22%). These results confirm the growing importance of ESBL-producing Enterobacteriaceae in UTIs and highlight the need for regular surveillance.